


USSN 10/719,187

CASE CT-2717-NP

What is claimed is:

1. (ORIGINAL) A compound of Formula I or a pharmaceutically acceptable salt thereof

5



wherein

R¹ is selected from the group consisting of straight or branched chain C₁₋₆ alkyl optionally substituted with amino, C₁₋₄ alkylamino or di(C₁₋₄ alkyl) amino, pyridinyl, pyrrolidinyl, piperidinyl, 2-thienyl, furanyl, imidazolyl, indenyl, benzofuran, C₃₋₆ cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, and trifluoromethoxy;

10

A is -CH=CH-, 1,1-cyclopropyl, or -(CH₂)_n-;

15 R² is C₁₋₄ alkyl, CF₃ or hydroxymethyl;


R³, R⁴, R⁵ and R⁶ each are independently hydrogen or fluoro;

n is an integer of 0 to 4, inclusive;

Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl and triazolyl optionally substituted with substituents independently selected from the group consisting of C₁₋₄ alkyl, halogen, amino and dimethylaminomethyl; provided that when Het is pyridinyl, pyrimidinyl or pyrazinyl, then A is not -CH=CH-.

20

- 25 2. (ORIGINAL) The compound of claim 1 having the Formula Ic or a pharmaceutically acceptable salt thereof



USSN 10/719,187

CASE CT-2717-NP

wherein

R¹ is selected from the group consisting of straight or branched chain C₁₋₆ alkyl optionally substituted with amino, C₁₋₄ alkylamino or di(C₁₋₄ alkyl) amino, pyridinyl, pyrrolidinyl, piperidinyl, 2-thienyl, furanyl, imidazolyl, indenyl, benzofuran, C₃₋₆ cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C₁₋₄ alkyl, C₁₋₄ alkoxy, trifluoromethyl, and trifluoromethoxy;

A is -CH=CH-, 1,1-cyclopropyl, or -(CH₂)_n;

R² is methyl or hydroxymethyl;

R³, R⁴, R⁵ and R⁶ each are independently hydrogen or fluoro;

n is an integer of 0 to 4, inclusive;

Het is selected from the group consisting of pyridinyl, pyrimidinyl, pyrazinyl, thiazolyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl and triazolyl

optionally substituted with substituents independently selected from the group consisting of C₁₋₄ alkyl, halogen, amino and dimethylaminomethyl;

provided that when Het is pyridinyl, pyrimidinyl or pyrazinyl, then A is not -CH=CH-.

3. (ORIGINAL) The compound of claim 1 selected from the group consisting of:

(S)-3-(2-fluoro-phenyl)-N-[1-(3-[1,2,4]triazol-1-yl-phenyl)-ethyl]-acrylamide;

(S)-3-(2-fluoro-phenyl)-N-[1-(3-thiazol-2-yl-phenyl)-ethyl]-acrylamide;

(S)-3-(2-fluoro-phenyl)-N-[1-(3-pyrazol-1-yl-phenyl)-ethyl]-acrylamide;

(S)-3-(2-fluoro-phenyl)-N-[1-(3-imidazol-1-yl-phenyl)-ethyl]-acrylamide;

(S)-4-phenyl-N-[1-(3-pyridin-3-yl-phenyl)-ethyl]-butyramide;

(S)-N-[1-(3-pyridin-3-yl-phenyl)-ethyl]-benzamide;

(S)-1H-imidazole-4-carboxylic acid [1-(3-pyridin-3-yl-phenyl)-ethyl]-amide;

(S)-N-[1-(3-imidazol-1-yl-phenyl)-ethyl]-3-phenyl-acrylamide;

(S)-N-[1-(3-oxazol-5-yl-phenyl)-ethyl]-3-phenyl-acrylamide;

(S)-3-phenyl-N-[1-(3-thiazol-2-yl-phenyl)-ethyl]-acrylamide;

(S)-3-phenyl-N-[1-(3-pyrazol-1-yl-phenyl)-ethyl]-acrylamide; and

USSN 10/719,187

CASE CT-2717-NP

(S)-benzofuran-2-carboxylic acid {1-[3-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-amide; or a pharmaceutically acceptable salt thereof.

4. (PREVIOUSLY PRESENTED) A pharmaceutical composition
5 comprising a therapeutically effective amount of the compound of claim 1 in
association with a pharmaceutically acceptable carrier, adjuvant or diluent.
5. (CANCELLED)
- 10 6. (CURRENTLY AMENDED) A method for the treatment of disorders
responsive to opening of the KCNQ potassium channels in a mammal in need
thereof, wherein said disorders are acute and chronic pain, migraine, neuropathic
pain, bipolar disorders, convulsions, mania, epilepsy, anxiety [[,] and depression
~~and neurodegenerative disorders~~, which comprises administering to said mammal
15 a therapeutically effective amount of the compound of claim 1.
7. (ORIGINAL) The method of claim 6 wherein said disorder is migraine.
8. (ORIGINAL) The method of claim 6 wherein said disorder is neuropathic
20 pain.